{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:58:33Z","timestamp":1792605513168,"version":"4.5.0"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1213\/ane.0b013e318222af2e","type":"journal-article","created":{"date-parts":[[2011,6,29]],"date-time":"2011-06-29T07:34:49Z","timestamp":1309332889000},"page":"1108-1119","source":"Crossref","is-referenced-by-count":38,"title":["Future Directions in Malignant Hyperthermia Research and Patient Care"],"prefix":"10.1213","volume":"113","author":[{"given":"Sharon J.","family":"Hirshey Dirksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn Green","family":"Larach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara W.","family":"Brandom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Parness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Scott","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Gangadharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Pezalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-28-20210902","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.bbamcr.2010.11.009","article-title":"Mechanistic models for muscle diseases and disorders originating in the sarcoplasmic reticulum.","volume":"1813","author":"Maclennan","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"R3-28-20210902","first-page":"1722","article-title":"Genetics of malignant hyperthermia.","volume":"6","author":"Brandom","year":"2006","journal-title":"SciWorldJ"},{"key":"R4-28-20210902","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1529\/biophysj.104.048447","article-title":"Distinct effects on Ca2 handling caused by malignant hyperthermia and central core disease mutations in RyR1.","volume":"87","author":"Dirksen","year":"2004","journal-title":"Biophys J"},{"key":"R5-28-20210902","doi-asserted-by":"crossref","first-page":"18465","DOI":"10.1074\/jbc.270.31.18465","article-title":"Identification of dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum.","volume":"270","author":"Parness","year":"1995","journal-title":"J Biol Chem"},{"key":"R6-28-20210902","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2044.2004.03658.x","article-title":"Dantrolenea review of its pharmacology, therapeutic use and new developments.","volume":"59","author":"Krause","year":"2004","journal-title":"Anaesthesia"},{"key":"R7-28-20210902","doi-asserted-by":"crossref","first-page":"26965","DOI":"10.1074\/jbc.272.43.26965","article-title":"Dantrolene inhibition of sarcoplasmic reticulum Ca2 release by direct and specific action at skeletal muscle ryanodine receptors.","volume":"272","author":"Fruen","year":"1997","journal-title":"J Biol Chem"},{"key":"R8-28-20210902","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1085\/jgp.118.4.355","article-title":"Effects of dantrolene on steps of excitation-contraction coupling in mammalian skeletal muscle fibers.","volume":"118","author":"Szentesi","year":"2001","journal-title":"J Gen Physiol"},{"key":"R9-28-20210902","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1113\/jphysiol.2009.172148","article-title":"Checking your SOCCs and feet: the molecular mechanisms of Ca2 entry in skeletal muscle.","volume":"587","author":"Dirksen","year":"2009","journal-title":"J Physiol"},{"key":"R10-28-20210902","doi-asserted-by":"crossref","first-page":"25645","DOI":"10.1074\/jbc.M110.104976","article-title":"Store-operated Ca2 entry in malignant hyperthermia-susceptible human skeletal muscle.","volume":"285","author":"Duke","year":"2010","journal-title":"J Biol Chem"},{"key":"R11-28-20210902","doi-asserted-by":"crossref","first-page":"13810","DOI":"10.1074\/jbc.M006104200","article-title":"Dantrolene inhibition of ryanodine receptor Ca2 release channels. Molecular mechanism and isoform selectivity.","volume":"276","author":"Zhao","year":"2001","journal-title":"J Biol Chem"},{"key":"R12-28-20210902","doi-asserted-by":"crossref","first-page":"33477","DOI":"10.1074\/jbc.M602306200","article-title":"Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor.","volume":"281","author":"Zhao","year":"2006","journal-title":"J Biol Chem"},{"key":"R13-28-20210902","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.bpj.2010.06.050","article-title":"Increased store-operated Ca2 entry in skeletal muscle with reduced calsequestrin-1 expression.","volume":"99","author":"Zhao","year":"2010","journal-title":"Biophys J"},{"key":"R14-28-20210902","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1124\/mol.107.043299","article-title":"Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene.","volume":"73","author":"Cherednichenko","year":"2008","journal-title":"Mol Pharmacol"},{"key":"R15-28-20210902","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1113\/jphysiol.2009.172155","article-title":"Store overload-induced Ca2 release as a triggering mechanism for CPVT and MH episodes caused by mutations in RYR and CASQ genes.","volume":"587","author":"MacLennan","year":"2009","journal-title":"J Physiol"},{"key":"R16-28-20210902","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.coph.2008.01.005","article-title":"Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm.","volume":"8","author":"Treves","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"R17-28-20210902","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1085\/jgp.200910328","article-title":"A malignant hyperthermia-inducing mutation in RYR1 (R163C): alterations in Ca2 entry, release, and retrograde signaling to the DHPR.","volume":"135","author":"Esteve","year":"2010","journal-title":"J Gen Physiol"},{"key":"R18-28-20210902","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.molmed.2009.10.005","article-title":"RNA-targeting approaches for neuromuscular diseases.","volume":"15","author":"Le Roy","year":"2009","journal-title":"Trends Mol Med"},{"key":"R19-28-20210902","doi-asserted-by":"crossref","first-page":"21813","DOI":"10.1073\/pnas.0912126106","article-title":"Ca2 dysregulation in Ryr1(I4895Twt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods.","volume":"106","author":"Zvaritch","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"R20-28-20210902","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cell.2008.02.042","article-title":"RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice.","volume":"133","author":"Durham","year":"2008","journal-title":"Cell"},{"key":"R21-28-20210902","doi-asserted-by":"crossref","first-page":"21996","DOI":"10.1073\/pnas.0911496106","article-title":"Characterization and temporal development of cores in a mouse model of malignant hyperthermia.","volume":"106","author":"Boncompagni","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"R22-28-20210902","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/ALN.0b013e3181c29504","article-title":"Exertional rhabdomyolysis and malignant hyperthermia in a patient with ryanodine receptor type 1 gene, L-type calcium channel alpha-1 subunit gene, and calsequestrin-1 gene polymorphisms.","volume":"112","author":"Capacchione","year":"2010","journal-title":"Anesthesiology"},{"key":"R23-28-20210902","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1213\/ane.0b013e3181a9d8d9","article-title":"The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia.","volume":"109","author":"Capacchione","year":"2009","journal-title":"Anesth Analg"},{"key":"R24-28-20210902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcp.10031","article-title":"Involvement of the cardiac ryanodine receptorcalcium release channel in catecholaminergic polymorphic ventricular tachycardia.","volume":"190","author":"Marks","year":"2002","journal-title":"J Cell Physiol"},{"key":"R25-28-20210902","first-page":"2230","article-title":"Leaky Ca2 release channelryanodine receptor 2 causes seizures and sudden cardiac death in mice.","volume":"118","author":"Lehnart","year":"2008","journal-title":"J Clin Invest"},{"key":"R26-28-20210902","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1253\/circj.CJ-10-0680","article-title":"Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S) knock-in mouse model.","volume":"74","author":"Kobayashi","year":"2010","journal-title":"Circ J"},{"key":"R27-28-20210902","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/343559a0","article-title":"Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.","volume":"343","author":"MacLennan","year":"1990","journal-title":"Nature"},{"key":"R28-28-20210902","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1471-2350-10-104","article-title":"The role of CACNA1S in predisposition to malignant hyperthermia.","volume":"10","author":"Carpenter","year":"2009","journal-title":"BMC Med Genet"},{"key":"R29-28-20210902","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/humu.20356","article-title":"Mutations in RYR1 in malignant hyperthermia and central core disease.","volume":"27","author":"Robinson","year":"2006","journal-title":"Hum Mutat"},{"key":"R30-28-20210902","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/emboj.2009.366","article-title":"DHPR alpha1S subunit controls skeletal muscle mass and morphogenesis.","volume":"29","author":"Pietri-Rouxel","year":"2010","journal-title":"Embo J"},{"key":"R31-28-20210902","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1096\/fj.05-4497fje","article-title":"Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse.","volume":"20","author":"Chelu","year":"2006","journal-title":"FASEB J"},{"key":"R32-28-20210902","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1093\/nar\/gkg509","article-title":"SIFT: predicting amino acid changes that affect protein function.","volume":"31","author":"Ng","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"R33-28-20210902","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/gtmb.2010.0036","article-title":"Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations.","volume":"14","author":"Flanagan","year":"2010","journal-title":"Genet Test Mol Biomarkers"},{"key":"R34-28-20210902","doi-asserted-by":"crossref","first-page":"C1094","DOI":"10.1152\/ajpcell.00173.2004","article-title":"Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling.","volume":"287","author":"Weiss","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"key":"R35-28-20210902","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/humu.20878","article-title":"Increasing the number of diagnostic mutations in malignant hyperthermia.","volume":"30","author":"Levano","year":"2009","journal-title":"Hum Mutat"},{"key":"R36-28-20210902","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1001\/jama.293.23.2918","article-title":"Malignant hyperthermia: update on susceptibility testing.","volume":"293","author":"Litman","year":"2005","journal-title":"JAMA"},{"key":"R38-28-20210902","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-1172-2-21","article-title":"Malignant hyperthermia.","volume":"2","author":"Rosenberg","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"R39-28-20210902","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1399-0004.2010.01493.x","article-title":"Novel missense mutations and unexpected multiple changes of RYR1 gene in 75 malignant hyperthermia families.","volume":"79","author":"Tammaro","year":"2011","journal-title":"Clin Genet"},{"key":"R40-28-20210902","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/FPC.0b013e3283339c08","article-title":"A mathematical model to improve on phenotyping for molecular genetic research in malignant hyperthermia.","volume":"19","author":"Ginz","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R41-28-20210902","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00000542-199404000-00008","article-title":"A clinical grading scale to predict malignant hyperthermia susceptibility.","volume":"80","author":"Larach","year":"1994","journal-title":"Anesthesiology"},{"key":"R42-28-20210902","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1001\/jama.293.23.2918","article-title":"Malignant hyperthermia: update on susceptibility testing.","volume":"293","author":"Litman","year":"2005","journal-title":"JAMA"},{"key":"R43-28-20210902","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1399-0004.2009.01251.x","article-title":"The ryanodine receptor type 1 gene variants in African American men with exertional rhabdomyolysis and malignant hyperthermia susceptibility.","volume":"76","author":"Sambuughin","year":"2009","journal-title":"Clin Genet"},{"key":"R44-28-20210902","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/bja\/aep204","article-title":"Genetic variation in RYR1 and malignant hyperthermia phenotypes.","volume":"103","author":"Carpenter","year":"2009","journal-title":"Br J Anaesth"},{"key":"R45-28-20210902","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/bja\/aep108","article-title":"Epigenetic allele silencing and variable penetrance of malignant hyperthermia susceptibility.","volume":"103","author":"Robinson","year":"2009","journal-title":"Br J Anaesth"},{"key":"R46-28-20210902","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/01.anes.0000271866.37280.85","article-title":"Delayed onset of malignant hyperthermia without creatine kinase elevation in a geriatric, ryanodine receptor type 1 gene compound heterozygous patient.","volume":"107","author":"Newmark","year":"2007","journal-title":"Anesthesiology"},{"key":"R47-28-20210902","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/00000542-200211000-00007","article-title":"Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility.","volume":"97","author":"Monnier","year":"2002","journal-title":"Anesthesiology"},{"key":"R48-28-20210902","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/00000542-200606000-00008","article-title":"Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing.","volume":"104","author":"Ibarra","year":"2006","journal-title":"Anesthesiology"},{"key":"R49-28-20210902","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/ALN.0b013e31819b5bdc","article-title":"Epidemiology of anesthesia-related mortality in the United States, 1999-2005.","volume":"110","author":"Li","year":"2009","journal-title":"Anesthesiology"},{"key":"R50-28-20210902","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/ALN.0b013e318190bb08","article-title":"Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005.","volume":"110","author":"Rosero","year":"2009","journal-title":"Anesthesiology"},{"key":"R51-28-20210902","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1213\/ane.0b013e3181ac1548","article-title":"Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005.","volume":"109","author":"Brady","year":"2009","journal-title":"Anesth Analg"},{"key":"R52-28-20210902","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1213\/ANE.0b013e3181c6b9b2","article-title":"Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006.","volume":"110","author":"Larach","year":"2010","journal-title":"Anesth Analg"},{"key":"R54-28-20210902","first-page":"700","article-title":"Incidence of malignant hyperthermia in Denmark.","volume":"64","author":"Ording","year":"1985","journal-title":"Anesth Analg"},{"key":"R55-28-20210902","first-page":"639","article-title":"Malignant hyperthermia in Austria: I. Epidemiology and clinical aspects.","volume":"35","author":"Mauritz","year":"1986","journal-title":"Anaesthesist"},{"key":"R56-28-20210902","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1213\/ane.0b013e3181adca28","article-title":"Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options.","volume":"109","author":"Benca","year":"2009","journal-title":"Anesth Analg"},{"key":"R57-28-20210902","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1213\/ANE.0b013e3181b5ae2d","article-title":"Core myopathies and risk of malignant hyperthermia.","volume":"109","author":"Klingler","year":"2009","journal-title":"Anesth Analg"},{"key":"R58-28-20210902","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1213\/ane.0b013e3181aa5cf6","article-title":"Malignant hyperthermia and muscular dystrophies.","volume":"109","author":"Gurnaney","year":"2009","journal-title":"Anesth Analg"},{"key":"R59-28-20210902","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1213\/ane.0b013e3181a7c8e5","article-title":"The myotonias and susceptibility to malignant hyperthermia.","volume":"109","author":"Parness","year":"2009","journal-title":"Anesth Analg"},{"key":"R60-28-20210902","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1213\/ane.0b013e3181ad63b4","article-title":"Malignant hyperthermia-like syndrome and carnitine palmitoyltransferase II deficiency with heterozygous R503C mutation.","volume":"109","author":"Hogan","year":"2009","journal-title":"Anesth Analg"},{"key":"R61-28-20210902","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1213\/ane.0b013e3181b493d4","article-title":"The association of malignant hyperthermia and unusual disease: when youre hot youre hot or maybe not.","volume":"109","author":"Davis","year":"2009","journal-title":"Anesth Analg"},{"key":"R62-28-20210902","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nm.1916","article-title":"Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle.","volume":"15","author":"Bellinger","year":"2009","journal-title":"Nat Med"},{"key":"R63-28-20210902","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/bja\/64.1.21","article-title":"Changes in resistance to mouth opening induced by depolarizing and non-depolarizing neuromuscular relaxants.","volume":"64","author":"van der Spek","year":"1990","journal-title":"Br J Anaesth"},{"key":"R64-28-20210902","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000542-198605000-00003","article-title":"Cerebral stimulation following succinylcholine in dogs.","volume":"64","author":"Lanier","year":"1986","journal-title":"Anesthesiology"},{"key":"R65-28-20210902","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1460-9592.2009.03032.x","article-title":"The place of suxamethonium in pediatric anesthesia.","volume":"19","author":"Rawicz","year":"2009","journal-title":"Paediatr Anaesth"},{"key":"R66-28-20210902","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/000992289703600102","article-title":"Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies.","volume":"36","author":"Larach","year":"1997","journal-title":"Clin Pediatr (Phila)"},{"key":"R67-28-20210902","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1123\/jsr.16.3.227","article-title":"Guidelines for return to duty (play) after heat illness: a military perspective.","volume":"16","author":"OConnor","year":"2007","journal-title":"J Sport Rehabil"},{"key":"R68-28-20210902","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1123\/jsr.16.3.215","article-title":"The heat tolerance test: an efficient screening tool for evaluating susceptibility to heat.","volume":"16","author":"Moran","year":"2007","journal-title":"J Sport Rehabil"},{"key":"R69-28-20210902","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/BOR.0b013e328314b7b4","article-title":"Genetic predisposition to statin myopathy.","volume":"20","author":"Vladutiu","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"R70-28-20210902","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies.","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve"},{"key":"R71-28-20210902","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1755-5922.2010.00237.x","article-title":"Statins alter intracellular calcium homeostasis in malignant hyperthermia susceptible individuals.","volume":"28","author":"Metterlein","year":"2010","journal-title":"Cardiovasc Ther"},{"key":"R72-28-20210902","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1542\/peds.111.6.1447","article-title":"Fatal malignant hyperthermia-like syndrome with rhabdomyolysis complicating the presentation of diabetes mellitus in adolescent males.","volume":"111","author":"Hollander","year":"2003","journal-title":"Pediatrics"},{"key":"R73-28-20210902","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/ALN.0b013e3181ee2cb7","article-title":"Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and present practice.","volume":"114","author":"Kim","year":"2011","journal-title":"Anesthesiology"},{"key":"R74-28-20210902","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/bja\/41.10.844","article-title":"Anaesthetic-induced malignant hyperpyrexia and a method for its prediction.","volume":"41","author":"Harrison","year":"1969","journal-title":"Br J Anaesth"},{"key":"R75-28-20210902","first-page":"639","article-title":"An activated charcoal filter for eliminating volatile anesthetics. A contribution to the management of malignant hyperthermia.","volume":"38","author":"Jantzen","year":"1989","journal-title":"Anaesthetist"},{"key":"R76-28-20210902","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1213\/ane.0b013e31818874d3","article-title":"Preparation of the Drager Fabius anesthesia machine for the malignant-hyperthermia susceptible patient.","volume":"107","author":"Gunter","year":"2008","journal-title":"Anesth Analg"},{"key":"R77-28-20210902","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1213\/ANE.0b013e318213fad7","article-title":"Activated charcoal effectively removes inhaled anesthetics from modern anesthesia machines.","volume":"112","author":"Birgenheier","year":"2011","journal-title":"Anesth Analg"}],"container-title":["Anesthesia & Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0b013e318222af2e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:16:59Z","timestamp":1786112219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000539-201111000-00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0b013e318222af2e","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}